MIFH
AXSM icon

Migdal Insurance & Financial Holdings’s Axsome Therapeutics AXSM Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-249
Closed -$9K – 608
2021
Q4 		$9K Sell
249
-151
-38% -$5.56K ﹤0.01% 606
2021
Q3 		$13K Buy
+400
New +$15.6K ﹤0.01% 582

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Migdal Insurance & Financial Holdings's AXSM Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Axsome Therapeutics (AXSM) in Q1 2022, closing a stake of 249 shares — an estimated $9K sold.

Migdal Insurance & Financial Holdings first reported a position in AXSM in Q3 2021 and held it in 2 quarters. The position peaked at $13K in Q3 2021. 174 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Axsome Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 249 Axsome Therapeutics shares in Q1 2022, an estimated $9K.
  • Migdal Insurance & Financial Holdings first reported a position in Axsome Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Axsome Therapeutics position peaked at $13K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.